A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule–Drug, Antibody–Drug, and Peptide–Drug Conjugates
- 3 July 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 34 (7) , 1205-1211
Abstract
We present the first in vivo comparative evaluation of chemically defined antibody-drug conjugates (ADCs), small molecule-drug conjugates (SMDCs), and peptide-drug conjugates (PDCs) targeting and activated by fibroblast activation protein (FAP) in solid tumors. Both the SMDC (OncoFAP-Gly-Pro-MMAE) and the ADC (7NP2-Gly-Pro-MMAE) candidates delivered high amounts of active payload (i.e., MMAE) selectively at the tumor site, thus producing a potent antitumor activity in a preclinical cancer model.Keywords
Funding Information
- Eidgen?ssische Technische Hochschule Z?rich
This publication has 33 references indexed in Scilit:
- Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryLeukemia & Lymphoma, 2016
- Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for EfficacyThe AAPS Journal, 2016
- Targeting folate receptor alpha for cancer treatmentOncotarget, 2016
- Antibody Drug Conjugates for Cancer TherapyPharmacological Reviews, 2016
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic AgentsJournal of Medicinal Chemistry, 2015
- Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivoNature Communications, 2013
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsInvestigational New Drugs, 2012
- Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via BivalencyBioconjugate Chemistry, 2009
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- TOXICITY OF CHEMOTHERAPYHematology/Oncology Clinics of North America, 1996